The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Neuromyelitis Optica Drug Market Research Report 2024

Global Neuromyelitis Optica Drug Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1381576

No of Pages : 88

Ask Your Query

Synopsis

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

The global Neuromyelitis Optica Drug market was valued at US$ 47 million in 2023 and is anticipated to reach US$ 58 million by 2030, witnessing a CAGR of 3.0% during the forecast period 2024-2030.

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Drug.

Report Scope

The Neuromyelitis Optica Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuromyelitis Optica Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neuromyelitis Optica Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company (Partial List)

  • Pfizer
  • Fresenius
  • Teva
  • Sandoz
  • Intas
  • Gyjtrs
  • NANG KUANG
  • Tianjin Kingyork
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • CBOP

Segment by Type

  • Glucocorticoids
  • Immunotherapies
  • Others

Segment by Application

  • Acute Attack
  • Remission Prophylactic Treatment

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Netherlands)
  • Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
  • Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuromyelitis Optica Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Glucocorticoids
1.2.3 Immunotherapies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Acute Attack
1.3.3 Remission Prophylactic Treatment
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Drug Market Perspective (2019-2030)
2.2 Neuromyelitis Optica Drug Growth Trends by Region
2.2.1 Global Neuromyelitis Optica Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neuromyelitis Optica Drug Historic Market Size by Region (2019-2024)
2.2.3 Neuromyelitis Optica Drug Forecasted Market Size by Region (2025-2030)
2.3 Neuromyelitis Optica Drug Market Dynamics
2.3.1 Neuromyelitis Optica Drug Industry Trends
2.3.2 Neuromyelitis Optica Drug Market Drivers
2.3.3 Neuromyelitis Optica Drug Market Challenges
2.3.4 Neuromyelitis Optica Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuromyelitis Optica Drug Players by Revenue
3.1.1 Global Top Neuromyelitis Optica Drug Players by Revenue (2019-2024)
3.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2019-2024)
3.2 Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neuromyelitis Optica Drug Revenue
3.4 Global Neuromyelitis Optica Drug Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Drug Revenue in 2023
3.5 Neuromyelitis Optica Drug Key Players Head office and Area Served
3.6 Key Players Neuromyelitis Optica Drug Product Solution and Service
3.7 Date of Enter into Neuromyelitis Optica Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuromyelitis Optica Drug Breakdown Data by Type
4.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2019-2024)
4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2025-2030)
5 Neuromyelitis Optica Drug Breakdown Data by Application
5.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2019-2024)
5.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neuromyelitis Optica Drug Market Size (2019-2030)
6.2 North America Neuromyelitis Optica Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neuromyelitis Optica Drug Market Size by Country (2019-2024)
6.4 North America Neuromyelitis Optica Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Drug Market Size (2019-2030)
7.2 Europe Neuromyelitis Optica Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neuromyelitis Optica Drug Market Size by Country (2019-2024)
7.4 Europe Neuromyelitis Optica Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Drug Market Size (2019-2030)
8.2 Asia-Pacific Neuromyelitis Optica Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuromyelitis Optica Drug Market Size (2019-2030)
9.2 Latin America Neuromyelitis Optica Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neuromyelitis Optica Drug Market Size by Country (2019-2024)
9.4 Latin America Neuromyelitis Optica Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Drug Market Size (2019-2030)
10.2 Middle East & Africa Neuromyelitis Optica Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuromyelitis Optica Drug Introduction
11.1.4 Pfizer Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Fresenius
11.2.1 Fresenius Company Detail
11.2.2 Fresenius Business Overview
11.2.3 Fresenius Neuromyelitis Optica Drug Introduction
11.2.4 Fresenius Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.2.5 Fresenius Recent Development
11.3 Teva
11.3.1 Teva Company Detail
11.3.2 Teva Business Overview
11.3.3 Teva Neuromyelitis Optica Drug Introduction
11.3.4 Teva Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.3.5 Teva Recent Development
11.4 Sandoz
11.4.1 Sandoz Company Detail
11.4.2 Sandoz Business Overview
11.4.3 Sandoz Neuromyelitis Optica Drug Introduction
11.4.4 Sandoz Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.4.5 Sandoz Recent Development
11.5 Intas
11.5.1 Intas Company Detail
11.5.2 Intas Business Overview
11.5.3 Intas Neuromyelitis Optica Drug Introduction
11.5.4 Intas Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.5.5 Intas Recent Development
11.6 Gyjtrs
11.6.1 Gyjtrs Company Detail
11.6.2 Gyjtrs Business Overview
11.6.3 Gyjtrs Neuromyelitis Optica Drug Introduction
11.6.4 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.6.5 Gyjtrs Recent Development
11.7 NANG KUANG
11.7.1 NANG KUANG Company Detail
11.7.2 NANG KUANG Business Overview
11.7.3 NANG KUANG Neuromyelitis Optica Drug Introduction
11.7.4 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.7.5 NANG KUANG Recent Development
11.8 Tianjin Kingyork
11.8.1 Tianjin Kingyork Company Detail
11.8.2 Tianjin Kingyork Business Overview
11.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Introduction
11.8.4 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.8.5 Tianjin Kingyork Recent Development
11.9 Baxter
11.9.1 Baxter Company Detail
11.9.2 Baxter Business Overview
11.9.3 Baxter Neuromyelitis Optica Drug Introduction
11.9.4 Baxter Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.9.5 Baxter Recent Development
11.10 CSL
11.10.1 CSL Company Detail
11.10.2 CSL Business Overview
11.10.3 CSL Neuromyelitis Optica Drug Introduction
11.10.4 CSL Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.10.5 CSL Recent Development
11.11 Grifols
11.11.1 Grifols Company Detail
11.11.2 Grifols Business Overview
11.11.3 Grifols Neuromyelitis Optica Drug Introduction
11.11.4 Grifols Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.11.5 Grifols Recent Development
11.12 Octapharma
11.12.1 Octapharma Company Detail
11.12.2 Octapharma Business Overview
11.12.3 Octapharma Neuromyelitis Optica Drug Introduction
11.12.4 Octapharma Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.12.5 Octapharma Recent Development
11.13 CBOP
11.13.1 CBOP Company Detail
11.13.2 CBOP Business Overview
11.13.3 CBOP Neuromyelitis Optica Drug Introduction
11.13.4 CBOP Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.13.5 CBOP Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock